Home  ›  Peer Reviewed Articles Over Muscles in the Eye

Peer Reviewed Articles Over Muscles in the Eye

Written By Monday, April 18, 2022 Add Comment Edit
U.Due south. markets close in 41 minutes

  • Due south&P 500

  • Dow thirty

  • Nasdaq

  • Russell 2000

  • Rough Oil

  • Gilded

  • Silver

  • EUR/USD

  • 10-Year Bond

  • GBP/USD

  • USD/JPY

  • BTC-USD

  • CMC Crypto 200

  • FTSE 100

  • Nikkei 225

Peer Review Affirms MiSight® 1 solar day Sustains Slowing of Heart Growth Over Six Years for Myopia Command

SAN RAMON, Calif., March 10, 2022 /PRNewswire/ -- A new peer review paper affirms that CooperVision® MiSight® 1 day contact lenses provide myopia command for nigh all children.†1 In the longest-running soft contact lens written report amongst children, xc% of myopic eyes responded† to MiSight® i 24-hour interval wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.1 Evidence also indicated a sustained slowing of centre growth with no loss of effectiveness over fourth dimension.‡one

CooperVision Logo (PRNewsfoto/CooperVision)
CooperVision Logo (PRNewsfoto/CooperVision)

These findings are published in the March 2022 edition of Optometry and Vision Science, the peer review journal of the American Academy of Optometry. Long-Term Issue of Dual-Focus Contact Lenses on Myopia Progression in Children: A vi-yr Multicenter Clinical Trial (Chamberlain P, et al.) is now available via Open Access.

The peer-reviewed six-twelvemonth paper complements additional CooperVision research demonstrating that the lens slows the rate of myopia progression past half at all observed ages. †§ane,ii The data also support that information technology'due south never likewise late to kickoff treatment, as the lens halves myopia progression in older children as well. ||two

"Myopia is a disease that progresses over many years, so demonstrating sustained efficacy is critical,"‡1 said Paul Chamberlain, BSc (Hons), MCOptom, the study'southward principal investigator and CooperVision Manager of Enquiry Programs. "Eye care professionals can prescribe MiSight® ane 24-hour interval with confidence knowing that the bulk of children reply to handling which lasts."

The MiSight® 1 solar day study is the world'due south longest running soft contact lens clinical trial for myopia management. This new paper joins a growing torso of peer-reviewed research stemming from the CooperVision MiSight® 1 solar day study including Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a half-dozen-yr Catamenia (Forest J, et al.) and Centric Length Targets for Myopia Command (Chamberlain P, et al.), as well as the recent Garland W. Clay Accolade winner, A iii-year Randomized Clinical Trial of MiSight Lenses for Myopia Control (Chamberlain P, et al.).

* U.South. Indications for Use: MiSight® i day (omafilcon A) soft (hydrophilic) contact lenses for daily vesture are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and accept a refraction of -0.75 to -iv.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded later on each removal.
† 90% of myopic eyes answer to MiSight® one 24-hour interval treatment; ages eleven-fifteen at start of wear, northward=xc.
‡ While optics are still growing; children fit ages 8-12 and followed for 6-years. due north=twoscore
§ Using measured and modeled data, pooled beyond ages (eight-17), MiSight® i mean solar day slowed myopia progression past an average of approximately 50%.
|| Children ages 8 to xv when starting MiSight i day treatment experienced a slowing of myopia progression.

About CooperVision
 CooperVision, a sectionalization of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, 2-week and monthly soft contact lenses that feature advanced materials and eyes, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products bachelor. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the market, creating real advantages for customers and wearers. For more data, visit www.coopervision.com.

Nearly CooperCompanies
 CooperCompanies ("Cooper") is a global medical device visitor publicly traded on the NYSE (NYSE: COO). Cooper operates through ii business organisation units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision intendance with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner back up. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more data, delight visit world wide web.coopercos.com.

Media Contact
 Hannah Barry, Advisor, McDougall Communications
hannah@mcdougallpr.com or +1-585-645-8985

1 Chamberlain P et al. Long-Term Upshot of Dual-Focus Contact Lenses on Myopia Progression in Children: A six-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
2 Arumugam B, Bradley A, Hammond D, Chamberlain P. Modelling Age Furnishings of Myopia Progression for the MiSight ane day Clinical Trial. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2333.

CooperVision® MiSight® 1 day is the ONE for myopia control in age-appropriate children as a contact lens specifically designed for myopia control and is FDA* approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment.† (PRNewsfoto/CooperVision)
CooperVision® MiSight® one day is the ONE for myopia control in age-advisable children as a contact lens specifically designed for myopia control and is FDA* approved to slow the progression of myopia in children aged 8-12 at the initiation of treatment.† (PRNewsfoto/CooperVision)
Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/peer-review-affirms-misight-i-day-sustains-slowing-of-eye-growth-over-half dozen-years-for-myopia-control-301499420.html

SOURCE CooperVision

herrtheavalogy.blogspot.com

Source: https://finance.yahoo.com/news/peer-review-affirms-misight-1-130000563.html

0 Response to "Peer Reviewed Articles Over Muscles in the Eye"

Post a Comment

Subscribe to: Post Comments (Atom)

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel